By W. Schramm, H. Krebs, S. Fleissner (auth.), Professor Dr. med. Inge Scharrer, Professor Dr. med. Wolfgang Schramm (eds.)

This publication comprises the contributions to the thirtieth Hemophilia Symposium, 1999. the most issues are HIV an infection, inhibitors in hemophilia, glossy therapy of hemophilia, drug-induced thrombophilia and pediatric hemostasiology. the amount is rounded off by means of quite a few unfastened papers and posters on hemophilia and linked topics.

Show description

Read or Download 30th Hemophilia Symposium Hamburg 1999 PDF

Best nonfiction_10 books

Immunotherapy with Intravenous Immunoglobulins

Using intravenous human antibodies within the therapy of fundamental immunodeficiencies is easily well-known. although, it truly is now obvious that in addition they have healing capability for quite a lot of different scientific problems. This booklet describes using human antibodies within the administration of secondary (virus-induced) immunodeficiencies, neonatal and perinatal infections, and autoimmunity.

Computational Seismology

Feel don't develop as quick as computational possi­ This publication comprises choices from Volumes bilities. I-V of the sequence "Computational Seismology," which in addition, for a few unusual cause, comput­ used to be initiated many years in the past by means of the Academy of ers often create a spirit of haste, notwithstanding they're Sciences of the USSR.

Additional resources for 30th Hemophilia Symposium Hamburg 1999

Example text

Blood samples will be sent to PD Dr. Oldenburg (Wiirzburg), and a back-up will be stored at Munich. Mutations within the FVIII gene will first be screened by SSCP, CMC, and DGGE procedures, and the mutation will be finally characterized by sequencing of the corresponding fragment. The Wiirzburg group has a database, currently comprising 500 hemophilia A patients, that is growing by Registry Munich Schramm Hemophilia ,samples from patient ith antibodies Schwaab samples without Iscreening results Fig.

This information is important for the pharmaceutical industry to improve their products with respect to an economically optimized therapy, to the formulation of less immunogenic factor VIII concentrates, and to the development of new therapeutic drugs for immune tolerance induction. In this study, five groups at four institutes will cooperate connecting several national and international efforts in hemophilia A research in Germany. It opens the possibility for tremendous synergistic effects: I.

Pape. 1995. Possible mechanism involving T-lymphocyte response to non- structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 346:1006-1007. 12. Inchauspe, G. 1999. DNA vaccine strategies for hepatitis C. I Hepatol. 30:339-46. 13. , G. Missale, S. Urbani, M. Pilli, C. Boni, C. Mori, A. Sette, M. Massari, S. Southwood, R. Bertoni, A. Valli, F. Fiaccadori, and C. Ferrari. 1999. Conserved hepatitis C virus sequences are highly immunogenic for CD4( +) T cells: implications for vaccine development.

Download PDF sample

Rated 4.11 of 5 – based on 33 votes